Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe page now displays revision v3.5.3, replacing the previous v3.5.2. This reflects a version update rather than a change to trial content.SummaryDifference0.0%

- Check13 days agoChange DetectedCity location text for Bucharest, Romania changed from the Romanian spelling (“București”) to the English spelling (“Bucharest”) while keeping the same address entry.SummaryDifference0.0%

- Check20 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2. No study content or features were changed.SummaryDifference0.0%

- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedPublication added under Publications: A Subgroup Analysis of Perioperative Pembrolizumab in Clinical Stage II NSCLC from KEYNOTE-671. Eur J Cardiothorac Surg. 2026 Mar 10; 68(3): ezag028.SummaryDifference0.0%

- Check42 days agoChange DetectedAdded Naples, Campania, Italy, 80131 and removed Napoli, Campania, Italy, 80131 from the locations list.SummaryDifference0.0%

- Check49 days agoChange DetectedThe page now shows Revision: v3.5.0 at the top, replacing Revision: v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.